Key statistics
On Tuesday, Stoke Therapeutics Inc (0GT:FRA) closed at 26.40, -19.02% below its 52-week high of 32.60, set on Oct 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 26.40 |
|---|---|
| High | 26.40 |
| Low | 26.40 |
| Bid | 27.00 |
| Offer | 27.40 |
| Previous close | 26.80 |
| Average volume | 47.11 |
|---|---|
| Shares outstanding | 57.12m |
| Free float | 54.80m |
| P/E (TTM) | 48.47 |
| Market cap | 1.83bn USD |
| EPS (TTM) | 0.66 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Press releases
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
More ▼
